The Fc and glycoengineered antibodies market is valued at USD 38.8 billion in 2024 growing at a CAGR of 5.86% during the forecast period 2024-2035.
Antibody-based pharmacological interventions have emerged as one of the fastest-growing segments within the biopharmaceutical industry, with a staggering number of approved monoclonal antibodies exceeding 120, and nearly 900 registered clinical trials for evaluation. This burgeoning field is projected to contribute significantly to global sales, surpassing USD 300 billion by 2025, underscoring its pivotal role in the healthcare landscape. The therapeutic efficacy of a drug, defined as its ability to produce the desired therapeutic effects in treating a particular disease, is a paramount consideration. A drug with high therapeutic efficacy offers improved treatment outcomes by increasing target specificity, reducing side effects, and extending the drug's half-life. To enhance the therapeutic efficacy of antibodies, various Fc and glycoengineering strategies have been developed recently.
Fc engineering focuses on modifying the Fc regions of antibodies to enhance their effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), thereby increasing the molecule's half-life. Conversely, glycoengineering optimizes the pharmacokinetic and pharmacodynamic properties of therapeutic antibodies by controlling the glycan composition within the molecule. These engineered antibodies are widely utilized in enhancing the anti-tumor potential of monoclonal antibodies. Currently, numerous drug developers and technology providers in this domain are actively engaged in developing various Fc and glycoengineered antibodies. Additionally, several major pharmaceutical companies have demonstrated a keen interest in these engineered antibodies, investing substantial resources in terms of time and capital into the Fc and glycoengineered antibodies market. Presently, over 150 Fc and glycoengineered antibodies have received global approval, with notable recent examples (in 2023) including Retifanlimab, Elranatamab, Glofitamab, and Tislelizumab.
Driven by the promising antibody-based drug pipeline, ongoing technical advancements, and the growing interest of biopharmaceutical developers, the Fc and glycoengineered antibodies market is poised to witness remarkable growth during the forecast period. This burgeoning field holds immense potential for improving therapeutic outcomes and advancing the frontiers of personalized medicine.
Key Market Segments
Type of Engineering
- Fc Engineered Antibodies
- Glycoengineered Antibodies
Type of Therapy
- Monotherapy
- Combination Therapy
- Both
Therapeutic Area
- Autoimmune Disorders
- Dermatological Disorders
- Oncological Disorders
- Rare Diseases
- Other Disorders
Route of Administration
- Intravenous Route
- Subcutaneous Route
- Intramuscular Route
Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the World
Research Coverage:
- The report studies the Fc and glycoengineered antibodies market based on type of engineering, type of therapy, therapeutic area, route of administration, and key geographical regions
- The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
- The report forecasts the revenue of market segments with respect to five major regions
- A general overview of antibodies, including structure, historical discovery timeline, isotypes, and mechanisms of action. Brief overview of Fc region, effector functions, Fc receptor types, engineering (glycoengineering, protein engineering, isotype chimerism), and future growth perspectives.
- Detailed assessment of over 170 marketed/development antibody programs for various indications. Analysis based on development phase, antibody type, engineering type, impact, target, therapy type, disease indication, therapeutic area, administration route, and popular Fc engineering technologies.
- Elaborate profiles of prominent Fc-engineered antibody developers, including company overview, financials, drug portfolio, recent developments, and future outlook.
- In-depth analysis of completed, ongoing, and planned clinical trials of Fc and glycoengineered antibodies based on trial parameters like registration year, status, phase, patient population, sponsor type, active players, study design, indication, and geography.
- Detailed analysis of partnerships since 2016 based on year, type, engineering type, therapeutic area, active players, and regional distribution.
- Analysis of grants (2019-2024) for Fc/glycoengineered antibody projects based on award year, amount, funding source, period, application type, purpose, activity code, study section, NIH departments, program officers, and recipient organizations.
- Elaborate patent analysis covering types, years, applicant types, geographies, CPC symbols, active players, benchmarking, and valuation of leading patents by citations.
- Detailed 2024-2035 market forecast estimating current size and future opportunity based on engineering types, therapy types, therapeutic areas, administration routes, key regions, and revenues from marketed/phase III drugs.
Key Benefits of Buying this Report
- The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
- Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
- The report provides stakeholders with a pulse on the Fc and glycoengineered antibodies market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Key Market Companies
- AbbVie
- Akesobio
- Alexion Pharmaceuticals
- Amgen
- AstraZeneca
- Boehringer Ingelheim
- Genentech
- MacroGenics
- MorphoSys
- Kyowa Kirin
- Xencor